ERBB2 and breast carcinoma: For example, trastuzumab is a monoclonal antibody which was first approved to treat patients with HER2+ breast cancer, and was subsequently approved in ERBB2-amplified NSCLC41 and HER2-overexpressing gastric adenocarcinoma.42